FDA approved Papzimeos (zopapogene imadenovec), the first-in-class, non-replicating adenoviral vector-based immunotherapy, ...

This first approved medical therapy for RRP generates an immune response against the causative HPV strains. It uses ...

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...

Dr Vinay Prasad will return to head the FDA’s Center for Biologics Evaluation and Research less than 2 weeks after being ousted.

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease ...

Shares of Precigen ( NASDAQ: PGEN) added ~94% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) ...

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...

In our Venable FDA Pulse series, we report on critical developments within the Food and Drug Administration (FDA or the Agency) that may affect ...

Shortly after that, the CDC overhauled its vaccine recommendations in COVID, nixing its endorsement of the shots for pregnant women and healthy children. At the time, RFK Jr. said he “couldn’t be more ...

President Trump’s effort to lessen crime in Washington, D.C., and launch a “beautification” effort is clashing with a long tradition of Republicans criticizing and outright writing off the ...

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

This episode of Pharma Pulse covers Vinay Prasad’s return to lead the FDA’s biologics center after a brief resignation, new ...